Agenus stock cut at Baird on FDA feedback (NASDAQ:AGEN)

Wall Street sign in Lower Manhattan, NYC

George Clerc

After falling nearly 60% in the previous session, Agenus shares (NASDAQ: Agen) Decreased by ~5% Shares of Baird fell Friday after the company downgraded its rating, citing FDA reactions to its colorectal cancer treatment combination BOT/BAL that led to selling.

After meeting withan agencyInterim data for phase 2.

The post Agenus stock cut at Baird on FDA feedback (NASDAQ:AGEN) first appeared on Investorempires.com.